Targeted protein degradation via PROTACs holds promise
for antiviral
therapy but is challenged by inefficient ternary complex formation.
We report the de novo design of PROTACs targeting the SARS-CoV-2 RNA-dependent
RNA polymerase (RdRp). Leveraging repurposed antiviral scaffolds and
optimizing E3 ligase ligands, we designed and screened 600 candidates.
Our integrated pipeline identified PROTAC 10, a molnupiravir-CRBN
conjugate, which demonstrated high-affinity binding (<i>K</i><sub>d</sub> = 1.09 nM), pronounced positive cooperativity (α
= 45.9), and effective CRBN-mediated RdRp degradation (DC<sub>50</sub> = 1.97 μM) in infected cells. PROTAC 10 was synthesized by
using modular click chemistry (CuAAC), strategically incorporating
a central triazole ring flanked by flexible alkyl spacers. It exhibited
potent antiviral activity (IC<sub>50</sub> = 3.12 μM). Molecular
dynamics simulations revealed that its engineered linker enhances
cooperativity, ternary complex stability (Δ<i>G</i><sub>TER</sub> = −247 kcal/mol), and chameleonic character.
This study provides a strategic framework to design antiviral PROTACs
through rational linker optimization that enables selective viral
protein degradation.